Yuxi Dong Jefferies LLC, Research Division All right. Good afternoon, everyone. Thanks for joining us here for Jefferies Global Healthcare Conference in London. My name is Clara Dong. I’m a biotech analyst here at Jefferies. So it’s my absolute pleasure to have the BeOne team here joining us here on the stage. We have CEO of BeOne, John Oyler; Aaron Rosenberg, CFO; and Mark Lanasa, the Chief Medical Officer of Solid Tumor. Welcome. Yuxi Dong Jefferies LLC, Research Division So it’s been a really eventful year for BeOne, I have to say, with your name change, achieving profitability and BTK inhibitor BRUKINSA is now leading the global revenue. And I have to say BeOne is probably among the fastest-growing biotech companies today. So for those less — might be less familiar with BeOne, can you talk about what makes BeOne’s strategy and development platform or infrastructure very unique for enabling those milestones here? John Oyler Co-Founder, Executive Chairman & CEO Sure. Thank you for the question, and it’s a pleasure to be here again this year. Very exciting times. We are a company that from the beginning, decided to do things quite differently. And we felt if we really want to transform the way medicine is made, have more attractive R&D returns, we needed to change the way we did things. And the vast majority of the money spent to make an oncology medicine, and we fight cancer is really spent in clinical trials, probably 75% to 90% of the cost of the medicine delivered to a patient.
https://seekingalpha.com/article/4844696-beone-medicines-ag-onc-presents-at-jefferies-london-healthcare-conference-2025-transcript?source=feed_all_articles
BeOne Medicines AG (ONC) Presents at Jefferies London Healthcare Conference 2025 Transcript
